The Tumor Immunology Lab explores the immune system's role in both preventing and combating cancer. Our focus is on understanding cancer immunosurveillance mechanisms and the immune response against established tumors when early-stage cancer cells evade elimination. Building on our previous discoveries, we concentrate our research on the interaction between two types of immune cells: tumor-specific T cells and macrophages, examining how they collaborate to recognize and eliminate malignancies. Our methodology includes conducting both in vitro and in vivo experiments using cell lines, functional immunological assays, live-cell imaging, experimental mouse models for lung, colon, skin, and breast cancers, as well as analyzing tumor tissues from patients with non-small cell lung cancer (NSCLC) and breast cancer. Our primary research aim is to deepen comprehension of the immune system's natural cancer-fighting processes, paving the way for the development of innovative cancer immunotherapy strategies.

• Cancer immunotherapy based on the activation of tumor-associated macrophages
• The potential of natural polysaccharides as immunotherapeutics
• Using tumor-infiltrating immune cells to predict patient’s survival and response to immunotherapy
• Cancer immunovirotherapy using viral vectors for cytokine gene delivery in tumors
• Cancer vaccines based on optimized activation of dendritic cells
• Development of tumor on-a-chip technology for advanced in vitro investigations

Contact information:

Alexandre Corthay, PhD
Head of Tumor immunology group
Mail address: Department of Pathology, Oslo University Hospital Rikshospitalet, P.O. Box 4950 Nydalen, NO-0424 Oslo, Norway. 
Visitor address: Visitor address: Department of Pathology, Oslo University Hospital, Rikshospitalet A3 building, Sognsvannsveien 20, Oslo. Office: room A3.3018.